Loading...
HLN logo

Haleon plcLSE:HLN Stock Report

Market Cap UK£29.2b
Share Price
UK£3.30
My Fair Value
UK£5.03
34.4% undervalued intrinsic discount
1Y-16.8%
7D-2.5%
Portfolio Value
​
View

Haleon plc

LSE:HLN Stock Report

Market Cap: UK£29.2b

Haleon (HLN) Stock Overview

Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details

HLN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health2/6
Dividends2/6

Rewards

Trading at 50.7% below our estimate of its fair value

Earnings are forecast to grow 6.09% per year

Earnings grew by 39.9% over the past year

Analysts in good agreement that stock price will rise by 24.9%

Risk Analysis

Has a high level of debt


HLN Community Fair Values

Create Narrative

See what 48 others think this stock is worth. Follow their fair value or set your own to get alerts.

HLN logo
Haleon

Emerging Markets And Digital Channels Will Transform Global Reach

Key Takeaways Expanding presence in emerging markets and leveraging digital channels drives strong brand growth, enhanced revenue prospects, and strategic geographic diversification. Investments in innovation, supply chain efficiencies, and premiumization strengthen long-term market share, margin expansion, and sustainable earnings growth.
View narrative
UK£4.14
FV
20.3% undervalued intrinsic discount
3.86%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
22 days ago author updated this narrative
HLN logo
Haleon

Aging Global Demand And Digital Reach Will Drive Consumer Healthcare

Key Takeaways Global expansion, innovation, and strong brand positioning are expected to drive multiyear revenue growth and margin improvement beyond current market expectations. Operational efficiencies, digital strategies, and China integration are likely to enhance profitability, free cash flow, and competitive advantage over the long term.
View narrative
UK£5.03
FV
34.4% undervalued intrinsic discount
4.38%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
2 months ago author updated this narrative
HLN logo
Haleon

Rising Regulatory Costs And Shifting Consumer Preferences Will Undermine Performance

Key Takeaways Rising regulatory costs and evolving health guidelines threaten margins, while core product reformulation may constrain long-term earnings and growth. Shifting consumer preferences and weak innovation expose Haleon to declining demand, competitive pressures, and limited ability to defend its leading brands.
View narrative
UK£3.2
FV
3.1% overvalued intrinsic discount
2.40%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 months ago author updated this narrative
View Stock Community

Haleon plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Haleon
Historical stock prices
Current Share PriceUK£3.30
52 Week HighUK£4.20
52 Week LowUK£2.74
Beta0.24
1 Month Change-8.92%
3 Month Change-12.77%
1 Year Change-16.79%
3 Year Change18.17%
5 Year Changen/a
Change since IPO7.02%

Recent News & Updates

Haleon (LON:HLN) Seems To Use Debt Quite Sensibly

Sep 15
Haleon (LON:HLN) Seems To Use Debt Quite Sensibly

We Ran A Stock Scan For Earnings Growth And Haleon (LON:HLN) Passed With Ease

Aug 28
We Ran A Stock Scan For Earnings Growth And Haleon (LON:HLN) Passed With Ease

Recent updates

Haleon (LON:HLN) Seems To Use Debt Quite Sensibly

Sep 15
Haleon (LON:HLN) Seems To Use Debt Quite Sensibly

We Ran A Stock Scan For Earnings Growth And Haleon (LON:HLN) Passed With Ease

Aug 28
We Ran A Stock Scan For Earnings Growth And Haleon (LON:HLN) Passed With Ease

Haleon plc (LON:HLN) Shares Could Be 38% Below Their Intrinsic Value Estimate

Jun 23
Haleon plc (LON:HLN) Shares Could Be 38% Below Their Intrinsic Value Estimate

Here's Why Haleon (LON:HLN) Can Manage Its Debt Responsibly

May 10
Here's Why Haleon (LON:HLN) Can Manage Its Debt Responsibly

Earnings Not Telling The Story For Haleon plc (LON:HLN)

Apr 09
Earnings Not Telling The Story For Haleon plc (LON:HLN)
User avatar

Sensodyne IND 20 And Cost Savings Will Strengthen Future Market Position

Haleon is driving growth through innovation and international expansion in emerging markets, enhancing market share and revenue.

Haleon (LON:HLN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 06
Haleon (LON:HLN) Shareholders Will Want The ROCE Trajectory To Continue

Haleon plc's (LON:HLN) Share Price Matching Investor Opinion

Dec 10
Haleon plc's (LON:HLN) Share Price Matching Investor Opinion

Haleon plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 03
Haleon plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Calculating The Fair Value Of Haleon plc (LON:HLN)

Nov 01
Calculating The Fair Value Of Haleon plc (LON:HLN)

Is Haleon (LON:HLN) Using Too Much Debt?

Oct 11
Is Haleon (LON:HLN) Using Too Much Debt?

Shareholder Returns

HLNGB PharmaceuticalsGB Market
7D-2.5%-2.3%-0.06%
1Y-16.8%-7.3%9.9%

Return vs Industry: HLN underperformed the UK Pharmaceuticals industry which returned -7.3% over the past year.

Return vs Market: HLN underperformed the UK Market which returned 9.9% over the past year.

Price Volatility

Is HLN's price volatile compared to industry and market?
HLN volatility
HLN Average Weekly Movement2.7%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.9%
10% least volatile stocks in GB Market2.5%

Stable Share Price: HLN has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: HLN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
171524,561Brian McNamarawww.haleon.com

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.

Haleon plc Fundamentals Summary

How do Haleon's earnings and revenue compare to its market cap?
HLN fundamental statistics
Market capUK£29.18b
Earnings (TTM)UK£1.52b
Revenue (TTM)UK£11.02b
19.4x
P/E Ratio
2.7x
P/S Ratio

Is HLN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLN income statement (TTM)
RevenueUK£11.02b
Cost of RevenueUK£4.02b
Gross ProfitUK£7.00b
Other ExpensesUK£5.48b
EarningsUK£1.52b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Feb 25, 2026

Earnings per share (EPS)0.17
Gross Margin63.56%
Net Profit Margin13.81%
Debt/Equity Ratio52.6%

How did HLN perform over the long term?

See historical performance and comparison

Dividends

2.1%
Current Dividend Yield
40%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/26 17:48
End of Day Share Price 2025/09/26 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haleon plc is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Warren AckermanBarclays
Iain SimpsonBarclays
Bethan DaviesBerenberg